Investments in respiratory infectious disease research 1997-2010: A systematic analysis of UK funding

BMJ Open

Volumn 4, Issue 3, 2014, Pages

  Head, Michael G ^a   Fitchett, Joseph R ^b   Cooke, Mary K ^a   Wurie, Fatima B ^a   Hayward, Andrew C ^a   Lipman, Marc C ^a   Atun, Rifat ^c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DIPHTHERIA; DRUG RESISTANT TUBERCULOSIS; FUNDING; HEALTH ECONOMICS; HUMAN; INFLUENZA; INVESTMENT; MEASLES; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; PUBLIC HEALTH; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; SYSTEMATIC REVIEW; TUBERCULOSIS; UNITED KINGDOM; COST OF ILLNESS; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE POLICY;

BIOMEDICAL RESEARCH; COST OF ILLNESS; FINANCIAL SUPPORT; FINANCING, GOVERNMENT; HEALTH POLICY; HUMANS; RESPIRATORY TRACT INFECTIONS; UNITED KINGDOM;

EID: 84897534971     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004600     Document Type: Article

References (33)

1. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
2. Walker CLF, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet 2013;381:1405-16.
3. Global tuberculosis report 2012. Geneva: World Health Organization, 2012. http://www.who.int/tb/publications/global-report/en/ (accessed 19 Aug 2013).
4. Blöndal K. Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. Bull World Health Organ 2007;85:387-90; discussion 391-4.
5. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
6. Influenza updates. World Health Organ. http://www.who.int/influenza/ surveillance-monitoring/updates/en/ (accessed 13 Jun 2013).
7. Cheng VCC, Lau SKP, Woo PCY, et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007;20:660-94. (Pubitemid 47623772)
8. The Lancet Infectious Diseases. Need for global cooperation in control of MERS-CoV. Lancet Infect Dis 2013;13:639.
9. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55.
10. Deer B. How the case against the MMR vaccine was fixed. BMJ 2011;342:c5347.
11. Department of Health. Latest whooping cough cases published by PHE. 2013. https://www.gov.uk/government/news/latest-whooping-cough-cases-published-by-phe (accessed 29 May 2013).
12. Vernon MK, Wiklund I, Bell JA, et al. What do we know about asthma triggers? A review of the literature. J Asthma 2012;49:991-8.
13. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:228-37.
14. Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2012;12:CD008319.
15. Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 2012;206:1652-9.
16. Head MG, Fitchett JR, Cooke MK, et al. UK investments in global infectious disease research 1997-2010: a case study. Lancet Infect Dis 2013;13:55-64.
17. Policy Cures. Neglected Disease Research and Development: the public divide. 2013. http://www.policycures.org/downloads/GF-report13-all-web.pdf (accessed 20 Mar 2014).
18. Head MG, Fitchett JR, Cooke MK, et al. UK investments in global infectious disease research 1997-2010: a case study. Lancet Infect Dis 2012. http://www.ncbi.nlm.nih.gov/pubmed/23140942 (accessed 17 Nov 2012).
19. ResearchInvestments.org. http://www.researchinvestments.org/ (accessed 30 May 2012).
20. Maharaj S, Kleczkowski A. Controlling epidemic spread by social distancing: do it well or not at all. BMC Public Health 2012;12:679.
21. Wise J. Three babies die in pseudomonas outbreak at Belfast neonatal unit. BMJ 2012;344:e592.
22. Loucq C. Vaccines today, vaccines tomorrow: a perspective. Clin Exp Vaccine Res 2013;2:4-7.
23. Al-Tawfiq JA, Zumla A, Memish ZA. Respiratory tract infections during the annual Hajj: potential risks and mitigation strategies. Curr Opin Pulm Med 2013;19:192-7.
24. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013. http://www.ncbi.nlm. nih.gov/pubmed/23531391 (accessed 25 Mar 2013).
25. Meyer J, McShane H. The next 10 years for tuberculosis vaccines: do we have the right plans in place? Expert Rev Vaccines 2013;12:443-51.
26. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol 2011;1:563-73.
27. Head MG, Fitchett JR, Cooke MK, et al. Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997-2010. J Antimicrob Chemother 2013. http://www.ncbi.nlm.nih.gov/pubmed/ 24038777 (accessed 26 Sep 2013).
28. Davies SC, Fowler T, Watson J, et al. Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance. Lancet 2013;381:1606-9.
29. Department of Health. Chief Medical Officer annual report: volume 2. London, 2013. https://www.gov.uk/government/publications/chief-medical-officer- annual-report-volume-2
30. Early announcement of NIHR themed call: Preventing the development and spread of Antimicrobial Resistance. 2013. http://rds-ne.nihr.ac.uk/2013/04/29/ early-announcement-of-nihr-themed-call-preventing-the-development-and-spread-of- antimicrobial-resistance/
31. Walwyn DR. Determining quantitative targets for public funding of tuberculosis research and development. Health Res Policy Syst 2013;11:10.
32. Treatment Action Group. 2013 Report on Tuberculosis Research Funding Trends, 2005-2012. 2013. http://www.treatmentactiongroup.org/tbrd2013
33. Johnson S. The Rise of Sovereign Wealth Funds. 2007. http://www.economia. puc-rio.br/mgarcia/Seminario/Seminario-textos/TheRiseofSovereignWealthFunds.pdf